A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia
B. Vormoor; G. J. Veal; M. J. Griffin; A. V. Boddy; J. Irving; L. Minto; M. Case; U. Banerji; K. E. Swales; J. R. Tall; A. S. Moore; M. Toguchi; G. Acton; K. Dyer; C. Schwab; C. J. Harrison; J. D. Grainger; D. Lancaster; P. Kearns; D. Hargrave; J. Vormoor
Author Information: Newcastle Cancer Centre at the Northern Institute for Cancer Research
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.